Bausch + Lomb will purchase all outstanding shares of leading ophthalmic laser company Technolas Perfect Vision.
Bausch + Lomb will purchase all outstanding shares of leading ophthalmic laser company Technolas Perfect Vision.
The companies, who entered into a co-promotion agreement in September 2011, will close the acquisition deal by the end of January 2013.
In earlier collaborations the companies have heavily promoted and further advanced the VICTUS femtosecond laser. The last twelve months has seen the VICTUS platform receive marketing approval from authorities in Europe and the US.
Dr Kristian Hohla, CEO of Technolas Perfect Vision, stated, "Our systems for refractive and cataract procedures complement Bausch + Lomb’s surgical portfolio and will help accelerate our expansion into the faster growing segments of the ocular surgery market. Together, we’ve proven our ability to introduce and market the highly innovative and differentiated VICTUS Femtosecond Laser Platform, and we look forward to working with our Bausch + Lomb colleagues to further advance ocular surgery using other laser-based technologies.”
John Barr, executive vice president and president of Bausch + Lomb Surgical, commented, "Our goal is to provide a compelling choice of products to fit the specific needs of their practice and patients. We intend to continue to invest in development and clinical programs that build upon their strong leadership position in laser-based surgical platforms. We look forward to working with Kristian and his team to provide physicians with systems that improve a wide range of sight-enhancing surgeries."
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.